41 results
8-K
EX-99.1
CRDF
Cardiff Oncology Inc
1 Jun 21
Regulation FD Disclosure
10:52am
Center Principal Investigator: Dr. Daniel H. Ahn
2021 Corporation Presentation I 31 1Onyvide Package Insert: https://www.accessdata.fda.gov
8-K
EX-99.1
CRDF
Cardiff Oncology Inc
12 Apr 21
Key Opinion Leader Webinar Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
8:33am
Leveraging the synergy between onvansertib and irinotecan + 5-FU 1Onyvide Package Insert: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015
8-K
EX-1.1
CRDF
Cardiff Oncology Inc
30 Sep 20
Cardiff Oncology Announces Proposed Public Offering
4:09pm
) of the Exchange Act after the date of this Agreement that is incorporated by reference in the Registration Statement.
(ii)General Disclosure Package … ) and the information included on Schedule C hereto, all considered together (collectively, the “General Disclosure Package”), nor (ii) any individual Limited Use
8-K
EX-99.2
qblpltdtww2d0
15 Jul 19
Regulation FD Disclosure
12:03pm
8-K
EX-1.1
pqe0hmco
6 Feb 15
Trovagene, Inc. Announces Pricing of Public Offering of Common Stock
12:00am
8-K
EX-10.1
qwr0jedo67t
4 Feb 09
Entry into a Material Definitive Agreement
12:00am
424B3
27r6tgo96 ttr0y4uue
7 Jul 06
Prospectus supplement
12:00am
POS AM
5vugme04mg
6 Jun 06
Prospectus update (post-effective amendment)
12:00am